NCT01704703View on ClinicalTrials.gov

Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Stage IV Colorectal Cancer
Interventions
DRUG

panitumumab

Panitumumab 6,0 mg/kg day 1 i.v. 60 min

DRUG

FOLFIRI

Irinotecan 180 mg/m2 day 1 i.v. 30-90 min Folinic acid 400 mg/ m2 day 1 i.v. 120 min 5-FU 400 mg/ m2 day 1 Bolus 5-FU 2.400 mg/ m2 day 1 i.v. 46 hours

Trial Locations (1)

28046

Spanish Cooperative Group for Digestive Tumour Therapy, Madrid

All Listed Sponsors
lead

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

OTHER

NCT01704703 - Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques | Biotech Hunter | Biotech Hunter